High-throughput sequencing detects early leukemia relapse

Share this article:

Compared with flow cytometry, a high-speed DNA-decoding technology known as high-throughput sequencing was able to identify minimal residual disease in nearly twice as many persons with leukemia.

Flow cytometry counts the number of cells with cancer-specific protein markers on their surface. In the United States, it is considered the gold standard for detecting minimal residual disease, a major predictor of cancer relapse characterized by a small number of cancer cells that survive treatment and persist in patients.

Now, a clinical trial has found high-throughput sequencing, which can determine thousands or millions of sequences of nucleotides along strands of DNA, to be at least 20 times more sensitive than flow cytometry in detecting minimal residual disease. In addition, high-throughput sequencing is highly automated and therefore less vulnerable to operator error and less time-consuming than flow cytometry.

For the study, Harlan Robins, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, Washington, and colleagues assessed minimal residual disease at posttreatment day 29 in 43 patients with acute T lymphoblastic leukemia. The investigators reported in Science Translational Medicine (2012;4[134]:134ra63) that high-throughput sequencing picked up minimal residual disease in 22 patients, compared with 12 patients for flow cytometry.

Patients whose cancer recurrence is detected early could be treated sooner, increasing their chance for survival. Eventually, high-throughput sequencing might even allow for much earlier diagnosing of leukemia and lymphoma than is currently possible. 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Gene likely to promote childhood cancers pinpointed

Researchers have identified a gene that contributes to the development of several childhood cancers, research that could lead to new strategies for targeting certain childhood cancers at a molecular level.

Flexible sigmoidoscopy screening reduces incidence and death rate for colorectal cancer

Screening with flexible sigmoidoscopy resulted in a reduced incidence and rate of death of colorectal cancer, compared with no screening, according to a recent study.

Black Women's Health Study (BWHS) shows exercise improves breast cancer risk for ...

This recently published study found strong evidence linking physical exercise to a lower rate of breast cancer in African American women, a group in which previous evidence has been lacking.